Loading...
Market
Story
Moderna Surpasses Q3 Estimates with $1.86B Revenue, $1.8B COVID Vaccine Sales, and $0.03 EPS
Nov 7, 2024, 11:57 AM
Moderna Inc. (MRNA) reported its third-quarter 2024 financial results, announcing revenue of $1.86 billion, exceeding the estimated $1.25 billion. The company's COVID-19 vaccine revenue was $1.8 billion, surpassing the estimated $1.2 billion, including $1.8 billion in Spikevax sales. Moderna achieved a net income of $13 million, compared to a net loss of $3.6 billion in the same period last year, resulting in earnings per share (EPS) of $0.03, outperforming the expected loss per share of $1.90. The company reported RSV vaccine revenue of $10 million. Moderna reiterated its 2024 expected product sales of $3.0 to $3.5 billion and year-to-date product sales of $2.2 billion. Cash and cash equivalents were reported at $9.2 billion.
View original story
Similar markets
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Products • 25%
No clear top-seller • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Vaccines • 25%
Equal Contribution • 25%
Majority from COVID-19 vaccines • 25%
Majority from oncology projects • 25%
Majority from mRNA projects • 25%
Majority from other sources • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Pfizer exceeds expectations • 25%
Moderna exceeds expectations • 25%
Both exceed expectations • 25%
Neither exceed expectations • 25%
COVID-19 vaccine • 33%
Flu vaccine • 33%
Other mRNA vaccines • 33%
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%